CCR4 and cancer: CCR4 immunotoxin is therefore expected to avoid resistance mechanisms attributed to poor accessory cell function in immunocompromised and heavily pretreated cancer patients, as commonly occur with mAb therapy (Vaughan et al., 2015; Vela et al., 2015).